Moderna, Inc. (MRNA)Healthcare | Biotechnology | Cambridge, United States | NasdaqGS
216.25 USD
+2.51
(1.174%)
⇧
(Oct. 13, 2026, 4 p.m.
EDT)
After hours: 215.20 -1.05 (-1.050%) ⇩ (Oct. 13, 2026, 6:40 p.m. EDT) |
Hot Take ↕ | Oct. 10, 2026, 11:11 a.m. EDT
Moderna is trading at a dangerous disconnect, priced at 52-week highs despite suffering four consecutive years of negative annual returns. While the stock has rallied strongly over the past two weeks, the underlying business remains unprofitable with negative operating margins and a return on equity of nearly -40%. The market is currently pricing in a recovery that analyst consensus does not support, with average price targets sitting at roughly $121, more than 40% below the current level. The options flow reveals a tug-of-war between momentum traders chasing the highs and hedgers protecting against a likely mean reversion. For a long-term investor, the structural deterioration over the last four years combined with the lack of dividend income makes this a weak hold. Short-term traders may find momentum favorable, but the valuation gap presents significant downside risk. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.732156 |
| AutoETS | 0.734852 |
| AutoARIMA | 0.735940 |
| MSTL | 0.736218 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 29% |
| H-stat | 9.42 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.038 |
| Excess Kurtosis | -1.13 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 19.036 |
| Revenue per Share | 5.662 |
| Market Cap | 86,334,767,104 |
| Forward P/E | -48.73 |
| Beta | 1.10 |
| Profit Margins | -141.43% |
| Website | https://www.modernatx.com |
As of Oct. 10, 2026, 11:11 a.m. EDT: Speculators are displaying a conflicted stance with heavy volume in both directions. Call buyers are aggressively targeting strikes well above the current price, including deep out-of-the-money positions at $290, suggesting a belief in a continued rally. Conversely, put buyers are establishing significant hedges at strikes just below the current level ($200-$210), indicating a fear of a sharp correction from the 52-week high. Implied volatility is elevated at deep strikes, reflecting uncertainty about whether the stock can sustain its recent surge.
| Attribute | Value |
|---|---|
| 52 Week Change | 7.142476 |
| Address1 | 325 Binney Street |
| All Time High | 497.49 |
| All Time Low | 11.54 |
| Ask | 228.12 |
| Ask Size | 1 |
| Audit Risk | 7 |
| Average Analyst Rating | 2.9 - Hold |
| Average Daily Volume10 Day | 19,159,770 |
| Average Daily Volume3 Month | 18,330,582 |
| Average Volume | 18,330,582 |
| Average Volume10Days | 19,159,770 |
| Beta | 1.095 |
| Bid | 206.04 |
| Bid Size | 1 |
| Board Risk | 7 |
| Book Value | 16.945 |
| City | Cambridge |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 10 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 216.25 |
| Current Ratio | 2.295 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 218.48 |
| Day Low | 204.7 |
| Debt To Equity | 19.036 |
| Display Name | Moderna |
| Dividend Yield | 0.0 |
| Earnings Call Timestamp End | 1,793,970,000 |
| Earnings Call Timestamp Start | 1,793,970,000 |
| Earnings Timestamp | 1,793,968,200 |
| Earnings Timestamp End | 1,793,968,200 |
| Earnings Timestamp Start | 1,793,968,200 |
| Ebitda | -2,195,000,064 |
| Ebitda Margins | -0.98519 |
| Enterprise To Ebitda | -37.121 |
| Enterprise To Revenue | 36.572 |
| Enterprise Value | 81,481,678,848 |
| Eps Current Year | -8.39789 |
| Eps Forward | -4.43761 |
| Eps Trailing Twelve Months | -7.98 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 141.4369 |
| Fifty Day Average Change | 74.813095 |
| Fifty Day Average Change Percent | 0.52895033 |
| Fifty Two Week Change Percent | 714.2476 |
| Fifty Two Week High | 227.46 |
| Fifty Two Week High Change | -11.210007 |
| Fifty Two Week High Change Percent | -0.04928342 |
| Fifty Two Week Low | 22.28 |
| Fifty Two Week Low Change | 193.97 |
| Fifty Two Week Low Change Percent | 8.706014 |
| Fifty Two Week Range | 22.28 - 227.46 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,544,193,000,000 |
| Float Shares | 372,063,894 |
| Forward Eps | -4.43761 |
| Forward P E | -48.731186 |
| Free Cashflow | 299,249,984 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 4,700 |
| Fullday Change | 1.4599915 |
| Fullday Change Percent | 0.6830689 |
| Fullday Price | 215.2 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,790,812,800 |
| Gross Margins | -0.66023004 |
| Gross Profits | -1,471,000,064 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.07337 |
| Held Percent Institutions | 0.80420995 |
| Implied Shares Outstanding | 399,235,889 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provides oncology therapeutics, such as intismeran autogene, cancer antigen therapy, t-cell engager, and cell therapy enhancer; and rare disease products, including propionic and methylmalonic acidemia, and cystic fibrosis. It has strategic alliances and collaborations with Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; immatics N.V.; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts. |
| Long Name | Moderna, Inc. |
| Market | us_market |
| Market Cap | 86,334,767,104 |
| Market State | POST |
| Max Age | 86,400 |
| Message Board Id | finmb_128680956 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -3,151,000,064 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 72,704,847,745 |
| Number Of Analyst Opinions | 18 |
| Open | 207.63 |
| Operating Cashflow | -1,073,000,000 |
| Operating Margins | -5.5793104 |
| Overall Risk | 10 |
| Payout Ratio | 0.0 |
| Phone | 617 714 6500 |
| Post Market Change | -1.050003 |
| Post Market Change Percent | -0.48555055 |
| Post Market Price | 215.2 |
| Post Market Time | 1,791,931,202 |
| Previous Close | 213.74 |
| Price Eps Current Year | -25.750515 |
| Price Hint | 2 |
| Price To Book | 12.761877 |
| Price To Sales Trailing12 Months | 38.749897 |
| Profit Margins | -1.41427 |
| Quick Ratio | 2.068 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | hold |
| Recommendation Mean | 2.86957 |
| Region | US |
| Regular Market Change | 2.5099945 |
| Regular Market Change Percent | 1.1743213 |
| Regular Market Day High | 218.48 |
| Regular Market Day Low | 204.7 |
| Regular Market Day Range | 204.7 - 218.48 |
| Regular Market Open | 207.63 |
| Regular Market Previous Close | 213.74 |
| Regular Market Price | 216.25 |
| Regular Market Time | 1,791,921,601 |
| Regular Market Volume | 13,361,426 |
| Return On Assets | -0.13256 |
| Return On Equity | -0.38998002 |
| Revenue Growth | 0.021 |
| Revenue Per Share | 5.662 |
| Sand P52 Week Change | 0.17502642 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 9 |
| Shares Outstanding | 399,235,889 |
| Shares Percent Shares Out | 0.0773 |
| Shares Short | 30,863,202 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 39,151,532 |
| Short Name | Moderna, Inc. |
| Short Percent Of Float | 0.094399996 |
| Short Ratio | 2.0 |
| Source Interval | 15 |
| State | MA |
| Symbol | MRNA |
| Target High Price | 200.0 |
| Target Low Price | 45.0 |
| Target Mean Price | 122.66667 |
| Target Median Price | 125.0 |
| Total Cash | 5,137,999,872 |
| Total Cash Per Share | 12.87 |
| Total Debt | 1,287,000,064 |
| Total Revenue | 2,228,000,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -7.98 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 73.53853 |
| Two Hundred Day Average Change | 142.71147 |
| Two Hundred Day Average Change Percent | 1.9406354 |
| Type Disp | Equity |
| Volume | 13,361,426 |
| Website | https://www.modernatx.com |
| Zip | 2,142 |